Skincare and device distributor AesthetiCare has launched a new cosmeceutical range designed specifically to rejuvenate, restore ad rebalance skin affected by the menopause.
The Emepelle range includes two products; Emepelle Serum and Emepelle Night Cream, which were launched in the UK at the Aesthetics Conference and Exhibition (ACE) and in the US at the American Academy of Dermatologists on March 1.
The company explains that Emepelle is powered by MEP technology, a patented, non-hormonal ingredient which is clinically proven to reinvigorate the natural functions of skin affected by low oestrogen levels during the menopause.
Roger Bloxham, managing director at AesthetiCare commented, “Currently, there are no other cosmeceuticals on the market that are clinically proven to safely and effectively target the root cause of skin ageing during menopause. This breakthrough innovation is a unique opportunity for professional skin clinics to empower women and help them manage the ageing of their skin before, during and after menopause."
New York based dermatologist Dr Diane Berson added, "There is a perception among women that ageing skin is a natural part of life and occurs as you age chronologically or through exposure to environmental factors, such as sunlight and pollution. Oestrogen loss, however, is a key factor in accelerated facial ageing."
She continued, "My patients with skin concerns, including dryness and ageing, don't want the side effects sometimes associated with other treatments for oestrogen deficiency. More importantly, these may not target the skin exclusively. I'm excited to be able to offer my patients a new solution that is safe and effective.”
According to AesthetiCare, both products are suitable for all skin types and are recommended for women who are in perimenopause, menopause or post menopause. They will be available to stock in clinics from April 1.